Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0S4VR
|
|||
Former ID |
DNC004334
|
|||
Drug Name |
(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine
|
|||
Synonyms |
CHEMBL74544; 1H-Benzimidazol-6-amine, N-1H-imidazol-2-yl-; 185312-13-4; (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine; BDBM50055831; AKOS027401219
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C10H9N5
|
|||
Canonical SMILES |
C1=CC2=C(C=C1NC3=NC=CN3)NC=N2
|
|||
InChI |
1S/C10H9N5/c1-2-8-9(14-6-13-8)5-7(1)15-10-11-3-4-12-10/h1-6H,(H,13,14)(H2,11,12,15)
|
|||
InChIKey |
NFSIDEIKDWWMOX-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Inhibitor | [1] |
Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Inhibitor | [1] | |
KEGG Pathway | cGMP-PKG signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Reactome | Adrenoceptors | |||
Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
Adrenaline,noradrenaline inhibits insulin secretion | ||||
G alpha (i) signalling events | ||||
G alpha (z) signalling events | ||||
Surfactant metabolism | ||||
WikiPathways | Monoamine GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
Platelet Aggregation (Plug Formation) | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.